| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 07/13/2005 | CN1210277C Heteroaryl diazabicycloalkanes, their prepn. and use |
| 07/13/2005 | CN1210274C Piperazine and piperidine derivatives |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210268C (Cyclo) alkyl substituted-gamma-aminobutyric acid derivatives (=GABA analogurs), their preparation and their use in the treatment of neurolog disorders |
| 07/13/2005 | CN1210263C N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 07/13/2005 | CN1210262C Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol |
| 07/13/2005 | CN1210256C Diacylhydrazine derivs |
| 07/13/2005 | CN1210043C Chinese herbal medicine for treating pains of neck shoulder, waist and legs |
| 07/13/2005 | CN1210037C Glucosamine and egg for reducing inflammation |
| 07/13/2005 | CN1210028C Aqueous liquid preparation |
| 07/13/2005 | CN1210022C Dichlofenac sodium slow-releasing preparation and its preparation method |
| 07/13/2005 | CN1210019C II type collagen water soluble dispersion composition, its preparation method and application |
| 07/12/2005 | US6916857 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 07/12/2005 | US6916840 Spla2 inhibitors |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916815 C-6 modified indazolylpyrrolotriazines |
| 07/12/2005 | US6916814 Methods of treating cytokine mediated diseases |
| 07/12/2005 | US6916810 αν integrin receptor antagonists |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916806 Such as 2-(2-isopropylphenyl)imino-5,5-dimethyl-1,3-thiazine which has binding activity to the cannabinoid type-2 receptors |
| 07/12/2005 | US6916799 Antiinflammatory agents; respiratory system disorders |
| 07/12/2005 | US6916797 α-arylethylpiperazine derivatives as neurokinin antagonists |
| 07/12/2005 | US6916788 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 07/12/2005 | US6916785 Homogeneous cyclosporin-containing solution |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | US6915802 Medicament pack |
| 07/12/2005 | CA2303421C Beta-defensins |
| 07/12/2005 | CA2303309C Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
| 07/12/2005 | CA1341485C Fusion proteins utilizing the decay accelerating factor membrane binding domain |
| 07/07/2005 | WO2005061523A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | WO2005061485A1 Process for making substituted pyrazoles |
| 07/07/2005 | WO2005061000A1 Remedy for angitis |
| 07/07/2005 | WO2005037783A3 Use of tricyclic compounds as glycine transport inhibitors |
| 07/07/2005 | US20050148777 (2R)-6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid; cyclooxygenase-2 mediated disorders |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148644 Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148632 Therapeutic agent for intestinal diseases and visceral pain |
| 07/07/2005 | US20050148627 Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148619 Sulfonamido ether substituted imidazoquinolines |
| 07/07/2005 | US20050148613 Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/07/2005 | US20050148608 Chymase enzyme inhibitors for drugs in vascular systems using sulfonylurea derivatives |
| 07/07/2005 | US20050148604 Increase the intracellular cAMP level and further inhibit the activation of T cells; allergic diseases, inflammatory or immunological diseases |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148588 LFA-1 antagonist compounds |
| 07/07/2005 | US20050148580 Non-opioid analgesics for chronic and acute pain; 1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione; modulation of the opioid and ORL I receptors; agonist or antagonist activity at the CNS mu, delta and kappa receptors greater than morphine |
| 07/07/2005 | US20050148578 1H-8-oxa-1-aza-dibenzo[e,h]azulene; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148577 2-methyl-1,8-dioxa-dibenzo[e,h]azulene; potentiation; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148576 Dibenzo[b.f]oxazolo-azulines, -oxepines and -thiepines; antiinflammatories; analgesics |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148550 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 07/07/2005 | US20050148549 Compositions and methods for inhibition of phospholipase a2 mediated inflammation |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148526 Methods of obtaining isoform specific expression in mammalian cells |
| 07/07/2005 | US20050148498 Metalloprotease inhibiting activity, in particular collagenase and gelatinase, treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease; treat inflammatory diseases: arthrosis, parodontosis or ulcers |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148006 Using modulator of guanosine diphosphate mannose-4,6 dehydratase for prevention and treatment of arthritis, sepsis, asthma, infection, stroke, reperfusion injury and organ transplant rejection |
| 07/07/2005 | US20050147680 Injectable veterinary composition for small animals |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147649 Method and dietary composition for improving fat digestibility |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | US20050147565 using inhalants containing aerosol suspensions comprising mometasone furoate, formoterol fumarate and 1,1,1,2,3,3,3,-heptafluoropropane |
| 07/07/2005 | CA2688944A1 Humanized anti-ngf antibodies |
| 07/07/2005 | CA2551181A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | CA2550843A1 Novel phenylalanine derivatives |
| 07/07/2005 | CA2550482A1 Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its uses for the treatment of angiogenic-related disorders |
| 07/07/2005 | CA2550283A1 Crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol |
| 07/07/2005 | CA2548494A1 Novel tricyclic spiroderivatives as modulators of chemokine receptor activity |
| 07/07/2005 | CA2540230A1 Aminopyridine-derivatives as inductible no-synthase inhibitors |
| 07/06/2005 | EP1550672A1 Chimeric antagonist anth1 |
| 07/06/2005 | EP1550660A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/06/2005 | EP1550461A1 Remedy for chronic disease |
| 07/06/2005 | EP1550456A2 Use of botulinum toxin in the treatment of burn pain |
| 07/06/2005 | EP1550454A1 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/06/2005 | EP1549756A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 07/06/2005 | EP1549660A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/06/2005 | EP1549658A1 Glucose-based compounds with affinity to p-selectin |
| 07/06/2005 | EP1549652A1 Fused azole-pyrimidine derivatives |
| 07/06/2005 | EP1549651A1 Kinase inhibitors |
| 07/06/2005 | EP1549648A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 07/06/2005 | EP1549640A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/06/2005 | EP1549637A1 1- (indol-3-yl)carbonyl piperazine derivatives |
| 07/06/2005 | EP1549634A1 Novel substituted indoles |
| 07/06/2005 | EP1549632A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 07/06/2005 | EP1549622A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
| 07/06/2005 | EP1549620A1 Indazolecarboxamide derivatives, preparation and use thereof as cdk1, cdk2 and cdk4 inhibitors |
| 07/06/2005 | EP1549619A1 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
| 07/06/2005 | EP1549598A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| 07/06/2005 | EP1549341A2 Novel tissue factor targeted antibodies as anticoagulants |
| 07/06/2005 | EP1549319A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 07/06/2005 | EP1549307A2 Agent for medicamentous treatment of acute and chronic pain |
| 07/06/2005 | EP1549301A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 07/06/2005 | EP1549291A1 Injection formulation |
| 07/06/2005 | EP1373256B1 Ccr5 antagonists useful for treating aids |
| 07/06/2005 | EP1230375B1 Inhibiting gene expression with dsrna |